Controversies in hormone treatment for prostate cancer

Mario Eisenberger

Research output: Chapter in Book/Report/Conference proceedingChapter


VACURG study 2, indicated that 1.0 mg/day was as effective as 5 mg/day DES in terms of deaths due to prostate cancer; however, there was a significant decrease in the incidence of severe and potentially fatal cardiovascular complications on the 1.0 mg/day arm. Both 5 mg/day and 1.0 mg/day DES had a lower incidence of deaths due to prostate cancer compared with a dose of 0.2 mg/day of DES or placebo. Unlike VACURG study 1, several patients on the placebo arm never received any treatment at the time of progression, and so study 2 is not perceived as an adequate test of the immediate versus deferred treatment question. Furthermore, VACURG study 2 was designed primarily to address the safety issue.

Original languageEnglish (US)
Title of host publicationTreatment Methods for Early and Advanced Prostate Cancer
PublisherCRC Press
Number of pages4
ISBN (Electronic)9780203091432
ISBN (Print)0415458935, 9780415458931
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Controversies in hormone treatment for prostate cancer'. Together they form a unique fingerprint.

Cite this